Sort
17,288 grants matching “multiple sclerosis”
Neural Representation of Reach-to-Grasp for Cortical FES Neuroprostheses
$0Abidemi B Ajiboye · Louis Stokes Cleveland Va Medical Center · IK2 · FY2015 · VA
Efficacy, tolerability, &safety of glatiramer acetate in multiple sclerosis
$0University Of Texas Hlth Sci Ctr Houston · M01 · FY2002 · RR
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
$0University Of Texas Hlth Sci Ctr Houston · M01 · FY2002 · RR
Immunoregulation of Myelin Specific T Lymphocytes
$0Arthur A. Vandenbark · Portland Va Medical Center · I01 · FY2009 · VA
Principles of Therapy in Cerebellar Disease: Explorations in Ion Channel Mutants
$0John S Stahl · Louis Stokes Cleveland Va Medical Center · I01 · FY2009 · VA
Developing and testing a comprehensive MS spasticity management program
$0Lucinda L Hugos · Portland Va Medical Center · I21 · FY2015 · VA
The Intron Debranching Enzyme (Dbr1) in Amyotrophic Lateral Sclerosis
$0Peter John Hart · South Texas Veterans Health Care System · I01 · FY2015 · VA
Accelerating remyelination using lanthionine ketimine derivatives
$0Douglas L Feinstein · Jesse Brown Va Medical Center · I01 · FY2022 · VA
Mechanisms of action: the effects of lipoic acid on macrophages,endothelial cells and CNS function in MS
$0Sonemany Salinthone · Portland Va Medical Center · I01 · FY2018 · VA
AVONEX IN TREATING HIGH DEVELOPMENT OF MULTIPLE SCLEROSIS
$0Ohio State University · M01 · FY2000 · RR
BLR&D Research Career Scientist Award Application
$0Gary Cecchini · Veterans Affairs Med Ctr San Francisco · IK6 · FY2020 · VA
BLR&D Research Career Scientist Award Application
$0Arthur A. Vandenbark · Portland Va Medical Center · IK6 · FY2022 · VA
ShEEP Request for Noldus EthoVision XT System
$0Adviye Ergul · Ralph H Johnson Va Medical Center · IS1 · FY2022 · VA
BLR&D Research Career Scientist Award Application
$0Arthur A. Vandenbark · Portland Va Medical Center · IK6 · FY2020 · VA
ORAL INTERFERON ALPHA--EFFECTS IN RELAPSING REMITTING MULTIPLE SCLEROSIS
$0University Of Texas Hlth Sci Ctr Houston · M01 · FY2002 · RR
Luminal Factors Affecting Duodenal Protection and Chemosensing
$0Jonathan D. Kaunitz · Va Greater Los Angeles Healthcare System · I01 · FY2023 · VA
AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS
$0University Of Texas Hlth Sci Ctr Houston · M01 · FY2002 · RR
Novel Pharmacological and Non-pharmacological Interventions for Bone Loss in SCI
$0Weiping Qin · James J Peters Va Medical Center · I01 · FY2020 · VA
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY
$0University Of Texas Hlth Sci Ctr Houston · M01 · FY2002 · RR
MURINE MODELS OF TSC1: MECHANISMS AND THERAPIES
$0Massachusetts General Hospital · P01 · FY2002 · NS
CORE--PATIENTS
$0Massachusetts General Hospital · P01 · FY2002 · NS
TNF alpha/glutamate induced cell death in Alzheimer's
$0University Of North Dakota · P20 · FY2002 · RR
Translational application of mouse models of melanoma brain metastases
$0Suzie Chen · Va New Jersey Health Care System · I01 · FY2022 · VA
Impact of Sleep Apnea in Elderly Veterans with Comorbid COPD
$0Susmita Chowdhuri · John D Dingell Va Medical Center · I21 · FY2018 · VA
Lipoic acid for the treatment of progressive multiple sclerosis
$0Rebecca I Spain · Portland Va Medical Center · I01 · FY2022 · VA